

Correction

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). *J Rheumatol* 2018; doi:10.3899/jrheum.170429. Numbers originally reported on page 373 of this article, column 2, second full paragraph, were incorrect. They should read as follows: “A total of 38 patients developed treatment-emergent antidrug antibodies (TE-ADA) during the extension period (4 PBO/IXEQ4W, 3 PBO/IXEQ2W, 6 ADA/IXEQ4W, 5 ADA/IXEQ2W, 12 IXE/IXEQ4W, 8 IXE/IXEQ2W). Twenty had confirmed neutralizing antibodies.”

The efficacy and safety conclusions reported in the article were not affected by these corrections and remain unchanged.

doi:10.3899/jrheum.170429.C1